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Objective. To identify whether a standardised Echinacea formulation is eﬀective in the prevention of respiratory and other
symptoms associated with long-haul ﬂights. Methods. 175 adults participated in a randomised, double-blind placebo-controlled
trial travelling back from Australia to America, Europe, or Africa for a period of 1–5 weeks on commercial ﬂights via economy
class. Participants took Echinacea (root extract, standardised to 4.4mg alkylamides) or placebo tablets. Participants were surveyed
before, immediately after travel, and at 4 weeks after travel regarding upper respiratory symptoms and travel-related quality of
life. Results. Respiratory symptoms for both groups increased signiﬁcantly during travel (P<0.0005). However, the Echinacea
group had borderline signiﬁcantly lower respiratory symptom scores compared to placebo (P = 0.05) during travel. Conclusions.
Supplementation with standardised Echinacea tablets, if taken before and during travel, may have preventive eﬀects against the
development of respiratory symptoms during travel involving long-haul ﬂights.
1.Introduction
Intercontinental air travel can be stressful, adding extra
strain on passenger’s physical and psychological health [1].
Studies have investigated the occurrence of nasal dryness [2],
the increased risk of developing upper respiratory disorders
such as allergic rhinitis and dry coughs [3], and attracting
virus- or bacteria-induced respiratory infections such as the
common cold during long-haul ﬂights [1, 4]. Almost 50% of
travellers experience some kind of illness while abroad, the
mostcommonbeinganupperrespiratoryinfection,typically
leading to 3-day debilitation during a 14-day trip [5]. Acute
respiratory tract infections like the common cold are mostly
caused by rhinoviruses [6] and respiratory viral infections
are also recognised as the most frequent cause of acute
exacerbations of asthma and chronic obstructive pulmonary
disease (COPD) [7].
To reduce adverse reactions to long distance ﬂights,
various interventions such as air humidiﬁcation and oxygen
supplementation have been trialled [8]; however, no research
has investigated the possible beneﬁt of a herbal medicine.
Herbal medicines, amongst other complementary and alter-
native medicines, are used by over half of the population
worldwide [9–11], and amongst the most widely used herbal
medicines is Echinacea, with millions of units sold annually.
Due to Echinacea’s in vitro anti-inﬂammatory [12, 13],
antiviral [14, 15] and immuno-modulating eﬀects [16, 17],
numerous clinical trials have investigated its eﬃcacy for
the treatment of the common cold. Although most studies
demonstrated positive eﬀects such as decreased severity and
duration of symptoms of the common cold when Echinacea
isgivenatﬁrstsignofinfection[18–20],outcomesareincon-
sistent [21] because of the variations in treatment protocols,
applied outcome measures, and Echinacea preparations [19,
20].
Preparations from three diﬀerent species, Echinacea
angustifolia, Echinacea purpurea, and Echinacea pallida, are
generallyreferredtoasEchinaceapreparations;howevertheir
p h y t o c h e m i c a lp r o ﬁ l ea n da c t i v i t yc a nd i ﬀer signiﬁcantly
[22]. Clinical trials mainly support eﬃcacy for preparations
from E. purpurea and partially E. angustifolia to treat
symptoms of the common cold [20]a n dt oh a v ea n2 Evidence-Based Complementary and Alternative Medicine
eﬀect on stress-induced factors: hsp70 and white blood cell
counts [23]. Alkylamides are considered to be part of the
active constituents in Echinacea as their bioavailability was
conﬁrmed by human pharmacokinetic studies with alky-
lamides detectable in plasma of healthy volunteers 30
minutes after Echinacea tablet ingestion [24, 25]. They have
shown to aﬀect the immune response through cannabinoid
type2dependentandindependentpathways,modulatingthe
production of cytokines such as TNFα [17] and IL-2 [26].
Echinacea’s preventative eﬀects for respiratory illness are
still debated [19, 27, 28] and diﬃcult for consumers to ascer-
tain [29]. Some previous studies used artiﬁcial rhinovirus
inoculation [28] or were not blinded and placebo controlled
[27]. The aim of our research was to identify whether an
alkylamide-standardised,bioavailableEchinaceaformulation
[23, 30]i ss a f ea n de ﬀective in the prevention of respiratory
and other travel-related symptoms during travel involving
long-haul ﬂights.
2.MaterialandMethods
2.1. Study Design. A randomised, double-blind placebo con-
trolled clinical trial was conducted between February 2009
and May 2010 in Australia with economy class passengers
travelling back, for a period of 1 to 5 weeks, from Australia to
America, Europe, or Africa on commercial ﬂights with a ﬂy-
ingtimeof15–25hoursandlessthan12-hourstopovers.The
clinical trial received ethical approval from the institutional
Human Research Ethics Committee (PHM0608HREC) and
was registered with the Australian New Zealand Clinical Tri-
als Registry (http://www.anzctr.org.au/ (ANZCTR 083687)).
Figure 1 outlines the study design for a participant trav-
elling for 35 days. For all participants treatment would com-
mence 14 days before ﬂying overseas and would complete
14 days after returning to Australia. The actual treatment
time varied between participants depending on their travel
duration. It ranged from a minimum of 5 weeks (if 7
days/1weekoftravel)to9weeks(if35days/5weeksoftravel).
Each participant completed three surveys: at 14 days
before travel (baseline), <1 week after travel (return), and at
4 weeks after returning from travel (followup). The surveys
contained questions relating to upper respiratory symptoms,
jet lag duration, headache, sleep disturbances, and cold sore
covering a period of the previous 4 weeks at each individual
time point (baseline, return, and followup).
2.2.StudyParticipantsandRandomisation. Participantswere
recruited through travel agencies, radio, newspaper, and TV
advertisements,andemailscirculatedtoallstaﬀandstudents
at a university and a teaching hospital on the Gold Coast,
Australia. Volunteers were included if they were 18–65 years
of age, in good general health and suﬀered from no previous
or current serious illness. Volunteers were excluded if they
had a known plant allergy, were suﬀering from respiratory
diseases (e.g., asthma, COPD), had any other condition
that could compromise the study or the participants health
(e.g., autoimmune disease, cystic ﬁbrosis), had received ﬂu
vaccinationwithin20daysofstartingthetrial,werelactating,
pregnant, or planning to become pregnant, or were on reg-
ular treatment with Echinacea, antibiotics, corticosteroids,
antihistamines, and immunosuppressants.
One hundred and seventy-ﬁve volunteers met the inclu-
sion criteria and were randomly assigned to trial tablets.
The random allocation sequence provided by the spon-
sor was computer generated using a randomisation plan
from http://www.randomization.com/ with randomisation
in blocks of 10. A list of consecutive study numbers was
generated. Treatment groups were allocated by trial staﬀ,b u t
the allocation was concealed by providing each participant
with a number. Participants, chief investigators, and trial
staﬀ were blinded to group allocation. To conﬁrm that
blinding was eﬀective, a subgroup of participants (n =
11 on placebo and n = 10 on Echinacea)w e r ea s k e dt o
speculate whether they were taking Echinacea or placebo.
Eleven participants identiﬁed themselves correctly, whereas
12 identiﬁed themselves incorrectly. There was an even
distribution of mismatches in the placebo and Echinacea
group providing further evidence of eﬀective randomisation.
2.3. Clinical Outcome Measurements and Statistical Analysis.
Upper respiratory symptom-related quality of life (QoL) was
measured using the questions from the 44-item Wisconsin
Upper Respiratory Symptom Survey (WURSS-44), which
was the primary outcome variable [31]. The WURSS-44 is
a responsive, reliable, and valid instrument for evaluating
QoL outcomes related to respiratory illness, measuring all
signiﬁcant health-related dimensions that are negatively
aﬀected by the common cold [31, 32]. It has been shown
to be a more powerful instrument for assessing respiratory-
relatedQoLthenthegeneral-health-relatedQoL,instrument
SF-36[32]andmeasurementscorrelatewellwithlaboratory-
assessed biomarkers [33]. The WURSS-44 includes 1 global
severity item, 32 symptom-based items, 10 functional QoL
items, and 1 global change item, all of which are based on
7-point Likert-type severity scales. A previous validation of
the instrument showed that a cumulative score should be
calculated by summing the severity scores of the ﬁrst 43
items with high severity scores indicating high symptom
load [31]. The median WURSS-44 score was calculated and
compared for both treatment groups using the nonpara-
metric Kolmogorov-Smirnov test for median diﬀerences in
independent samples. Symptoms in our survey were assessed
over the past 4 weeks rather than for the past 24h to
accommodate the travel trial setting. A minimal important
diﬀerence (MID) is the term generally used to quantify the
minimum amount of positive change that patients perceive
and would accept an associated treatment as being beneﬁcial
or worth taking—a clinically signiﬁcant eﬀect [34]. For the
WURSS-44 score, an MID of 16.7 points was determined
[32]. Therefore, individuals that presented with a respiratory
disorder symptoms score of 17 and above (RDS+) were
compared in both groups at baseline, return, and followup.
Diﬀerence in the prevalence (or proportion) of RDS+
individuals between groups at followup was statistically
comparedusinga2 ×2chi-squaredtestofindependenceand
the Odds Ratio. The amount of missing data was diﬀerentEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Study design of the trial for a travel time of 35 days.
among variables but on average was less than 10%. We an-
alysed observed data, only that is, did not impute data or
conduct missing at random analyses.
In addition 15 questions were designed and assessed as
secondary outcome measures for occurrence and duration
of jet lag, headache, sleep pattern, and herpes simplex sores.
t-tests and chi-square tests were used to analyse diﬀerences
between groups regarding headache, cold sore, and sleep
disturbances. Results were considered signiﬁcant when the
P value was ≤0.05. All statistical analysis carried out was
based on intention to treat (ITT) using the program PASW
Statistics (SPSS) version 18.0.
Study participants were asked to complete a diary during
the trial to record any upper respiratory symptoms, possible
travel stress symptoms such as jet lag duration, headache,
sleep disturbances, cold sore, headache, administration of
sick dose, as well as additional health issues or disease symp-
toms and additional medication taken. The diary helped
participants with recalling information when completing the
surveys and allowed researchers to identify possible inconsis-
tencies in data documentation. Participants were contacted
by trial staﬀ via phone a couple of days before leaving
Australia and following their return to Australia, to ensure
participants well-being, correct dosing, compliance, diary
completion and to make ﬁnal appointments. Participants
were provided with an emergency phone number which they
could contact 24 hours, 7 days a week, especially while being
overseas.
2.4. Sample Size Calculation. Studies estimate the incidence
of respiratory problems from 11%—in ﬂight emergencies—
based on respiratory problems [35] to 50% health-related
problems with the 2nd most common cause being respi-
ratory problems [36]. For this study it was estimated that
4 out of 10 participants in the placebo group (40%) will
be RDS+ at followup compared to 20% in the Echinacea
group, which equates to a clinically signiﬁcant decreased risk
of RDS (OR∼2). It was also previously reported that using
the WURSS-44 to assess symptomatic patients a two-armed
RCT would require 92 participants in total to detect an MID
as being statistically signiﬁcant [32]. We concluded that a
sample size of approximately 180 would yield at least 80%
power to detect a treatment eﬀect as statistically signiﬁcant
at the 0.05 alpha level.
2.5. Treatment. The Echinacea tablet preparation used
was the commercially available Echinacea Premium tablets
(MediHerb brand) manufactured by Integria Healthcare Pty
Ltd. (AustL no. 75124) standardised to 4.4mg alkylamides.
The tablets contained 112.5mg Echinacea purpurea 6:1
extract(equivalentto675mgdryroot)and150mgEchinacea
angustifolia 4:1 extract (equivalent to 600mg dry root).
Phytochemical proﬁles for these tablets were established for
previous batches [25, 30] and also determined for the batch
used in this study (Table 1). Placebo tablets were manufac-
tured to match the Echinacea tablets in size, excipients, and
colour. Both sets of tablets were coated with a brown colour
and hypromellose to make them indistinguishable. Tablets
were packed in identical amber glass bottles with identical
labelling. Labelling only identiﬁed the patient number.
2.6. Dosing. For our study medication, the manufacturer
recommends for adult patients one tablet three times daily
(3825mgdryrootequivalent/day)andifrequiredanincrease
to two tablets three times daily. This lies within the dosage
range commonly recommended for Echinacea formulations.
For ease of adherence and compliance with the dosing
schedules whilst travelling and experiencing time zone chan-
ges, dosing was undertaken twice daily, either as one tablet
(priming, overseas, and after-travel dose) or two tablets4 Evidence-Based Complementary and Alternative Medicine
Table 1: Alkylamide content per Echinacea tablet used as trial
medication.
Alkylamide name MW Structure mg/tableta
(2E/Z,4Z/E)-N-(2-
Methylpropyl)undeca-2,4-diene-
8,10-diynamide
229 Diene 0.247
(2E,4Z)-N-(2-
Methylpropyl)dodeca-2,4-diene-
8,10-diynamide
243 Diene 0.505
(2E,4E,8Z/E,10Z/E)-N-(2-
Methylpropyl)dodeca-2,4,8,10-
tetraenamide
247 Diene 1.504
(2E,4E,8Z)-N-(2-
Methylpropyl)dodeca-2,4,8-
trienamide
249 Diene 0.078
(2E,4E)-N-(2-
Methylpropyl)dodeca-2,4-
dienamide
251 Diene 0.166
(2E,4Z)-N-(2-Methylbutyl)dodeca-
2,4-diene-8,10-diynamide 257 Diene 0.130
(2E/Z)-N-(2-Methylpropyl)undec-
2-ene-8,10-diynamide 231 Monoene 0.699
(2E)-N-(2-Methylpropyl)dodec-2-
ene-8,10-diynamide 245 Monoene 0.452
(2E,7Z)-N-(2-
Methylpropyl)trideca-2,7-diene-
10,12-diynamide
257 Monoene 0.081
(2E0-N-(2-Methylbutyl)dodec-2-
ene-8,10-diynamide 259 Monoene 0.186
(2E,9Z)-N-(2-
Methylpropyl)pentadeca-2,9-diene-
12,14-diynamide
285 Monoene 0.330
(2E,9Z)-N-(2-
Methylpropyl)hexadeca-2,9-diene-
12,14-diynamide
299 Monoene 0.041
Total 4.419
aAlkylamide concentrations were determined by liquid chromatography
mass spectrometry using a Shimadzu HPLC system coupled to a Shimadzu
2010EV single quadrupole mass spectrometer operating with an APCI
interface as described for a previous batch [25].
during the stressful ﬂying time (ﬂying dose). An example of
the protocol for 5 weeks of travel is given below in Table 2
(also see Figure 1 for study layout), with Day 0 being the ﬁrst
day of travel and Day 35 being the return day. For shorter
travel periods, the period for the overseas dose between days
8 and 32 was shortened, reﬂecting the time the participant
wasspendingabroad.Allotherdosing,beforeandaftertravel
including during the washout period, remained the same for
each participant.
Participantswereallowedtotakeasickdose(threetablets
twice a day) if cold- or ﬂu-like symptoms occurred. The sick
dosec ouldonlybetak enforupt o8c onsecuti v eda ysortwic e
for 4 days during the whole travel period. Compliance was
assessed by calculating the percentage of tablets taken against
total tablets expected to be taken of the treatment period.
Table 2: Treatment protocol used for 35 days of travel.a
Days Protocol Dosage
−14 to −3 Priming dose One tablet twice
ad a y
−2 to +7 Flying dose Two tablets
twice a day
+8 to +32 Overseas dose One tablet twice
ad a y
+33 to +42 Flying dose Two tablets
twice a day
+43 to +49 After-travel dose One tablet twice
ad a y
aAlso see Figure 1 for study layout.
3. Results
The ﬂow of participants through the trial between February
2009 and May 2010 is summarised in Figure 2. Six hundred
and ﬁfty-eight people were screened, with a number deemed
ineligible by inclusion criteria: plant allergy, inappropriate
destination,and/orextendedstopoversduringtravel(>12h).
Reasons for declining participation included not wanting to
be on placebo, travel cancellation, tablet size, and personal
circumstances. Of the 175 trial participants, 170 completed
the initial survey. Thus ITT analysis was performed on 170
participants. All three completed surveys were returned by
143 participants while 27 were lost to followup.
3.1. Baseline Analysis. Of the 170 participants analysed,
85 were assigned Echinacea tablets and 85 were assigned
placebo. Sixty-seven percent of participants were women.
Table 3 shows the baseline characteristics of the trial groups.
On average, participants were 43 years old, weight 76kg,
had normal blood pressure, and travelled for 23 days.
Travel was mostly holiday related. There were no statistically
signiﬁcant diﬀerences between the Echinacea and placebo
group for the test variables at baseline (Table 3). Thus,
the two treatment groups can be considered reasonably
well balanced at baseline.
3.2. Primary Outcomes. Figure 3 shows the median WURSS-
44 symptom scores for the placebo and Echinacea group
at each time point. Compared to baseline (before travel),
the average WURSS-44 scores for both groups increased
during travel (measured retrospectively at return) (P<
0.0005). When comparing both groups with each other at
each individual time point, the WURSS-44 scores did not
diﬀer signiﬁcantly before travel (baseline) (P = 0.17) and
during the 4 weeks after travel (measured retrospectively at
followup) (P = 0.18). However, at during travel (measured
retrospectivelyatreturn),theplacebogrouphadsigniﬁcantly
higher WURSS-44 scores on average compared to the
Echinacea group (26 versus 13, P = 0.05).
When comparing the percentage of participants consid-
ering themselves to be aﬀected by respiratory illness (score >
17), there was no signiﬁcant diﬀerence between both groups
at baseline (before travel) (P = 0.19). However, the resultsEvidence-Based Complementary and Alternative Medicine 5
Analysed (n = 85)
Excluded from analysis (n = 3)
Reason: changed their mind
Reasons: death in family, non-
contactable, got too busy, discontinued
intervention (n = 8) (reasons: got sick (4),
ADR (2), lost interest (2))
Lost to followup (n 10) =
Reasons: noncontactable, discontinued
intervention (n = 7) (reasons: lost tablets
(1), got sick (3), too busy (2), ADR (1))
Allocated to intervention (n = 87)
Received allocated intervention (n = 85)
Did not receive allocated intervention
(n = 2) reasons: trip cancelled, lost interest
Analysed (n = 85)
Excluded from analysis (n = 2)
Reason: trip cancelled, trip cancelled, lost
interest
Analysis
Followup
Assessed for eligibility (n = 658)
Excluded (n = 483)
Not meeting inclusion criteria (n = 274)
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Other reasons (n = 10)
Randomization (n = 175)
Allocated to intervention (n = 88)
Received allocated intervention (n = 85)
Did not receive allocated intervention
(n = 3) reason: changed their mind
Echinacea Placebo
Allocation
Lost to followup (n = 17)
Figure 2: Flowchart of participants in the trial.
Table 3: Comparison of demographics and outcome measures of trial groups at baseline (before travel).
Variable Total
(n = 170)
Echinacea
(n = 85)
Placebo
(n = 85) P valuea
Age in years-mean (SD) 43 (14) 44 (13) 42 (14) 0.21
Females (%) 113 (67) 62 (55) 51 (45) 0.10
Weight in kg (SD) 75.6 (17.8) 75.0 (16.8) 76.0 (19.2) 0.48
BMI (SD) 26.0 (5.3) 25.8 (5.0) 26.3 (5.6) 0.55
Diastolic blood pressure
(SD) 86.7 (8.4) 85.8 (8.7) 88.1 (7.9) 0.10
Systolic blood pressure
(SD) 110.6 (11.8) 111.1 (11.9) 109.7 (13.5) 0.48
Duration of travel in days
(SD) 23 (8) 23 (8) 22 (8) 0.45
bRDS + (%) 39 (23) 17 (20) 22 (26) 0.38
cMedian WURSS-44 score 7 5 8 0.17
Cold sore (%) 63 (37) 31 (36) 32 (38) 0.87
Sleep diﬃculties (%) 40 (24) 21 (25) 19 (22) 0.72
Headache suﬀerer (%) 66 (39) 32 (38) 34 (40) 0.85
aAll P values are two-tailed comparing Echinacea to placebo. Values are either means with standard deviations (SD) or frequencies with percentages (%).
bRDS+ indicates a Respiratory Disease Symptoms score > 17. cMedian WURSS-44 score refers to the median Wisconsin Upper Respiratory Symptom score.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: y-axis shows average WURSS-44 scores for each treat-
ment group at the 3 time points surveyed (x-axis), n = 170.
from the survey completed immediately after return from
travel showed a signiﬁcantly reduced percentage of RDS+
aﬀected participants in the Echinacea g r o u pc o m p a r e dt o
placebo (43% versus 57%, P = 0.05) during travel. This
diﬀerence was further substantiated during the 4 weeks after
travel (survey at followup) where there was a signiﬁcantly
lower percentage of illness in the Echinacea-treated group
compared to placebo (i.e., 25% versus 39%) which corre-
sponds to ∼50% relative reduction (P = 0.03). This implies
that patients will be 50% less likely to suﬀer respiratory
disorder symptoms scores of 17 and above (RDS+), which
they consider treatment worthy.
3.3. Secondary Outcomes. Given Echinacea’s anti-inﬂamma-
tory and antiviral eﬀects we also investigated whether this
herbal medicine could be beneﬁcial in the prevention and
treatment of headache and cold sores, respectively. However,
there was no signiﬁcant diﬀerence between the placebo and
Echinacea group with regards to sleep disturbances and the
prevalence of headache and cold sores at any of the time
points (data not shown).
3.4. Compliance and Adverse Events. Treatment compliance
was high in both groups with no signiﬁcant diﬀerence in
theircompliancetothestudymedication(Echinacea=92.5%
versus Placebo = 95%, P = 0.49). Similarly, the use of sick
doses was not signiﬁcantly diﬀerent between both groups
(Echinacea = 47% versus Placebo = 53%, P = 0.77).
Overall, treatment was well tolerated. Adverse events
such as (i) vomiting and headache, (ii) heartburn, and (iii)
diarrhoea were reported by only 3 participants, respectively,
but a causal relationship between Echinacea and the events
could not be established. The participant who reported
headacheandvomitingwaslaterunblindedastakingplacebo
tablets and the participant who reported heartburn and
diarrhoea were later unblinded as taking Echinacea tablets.
However, the participants who reported heartburn was also
taking aspirin and several other medicines such as sleeping
tablets.
However, two participants, who were later identiﬁed as
taking Echinacea, reported symptoms that were regarded as
potential adverse eﬀects from Echinacea. Both participants
reported tingling and burning of the tongue and mouth
immediately after taking tablets. While one participant
stopped the tablets immediately and the symptoms disap-
peared within 24h, the other participant continued the trial
medication for over 3 weeks while symptoms worsened (sore
throat, achy head, swollen legs, fever, rash, redness and
itchiness on feet and legs, and a general feeling of being
unwell). Following the cessation of the trial medication,
symptoms disappeared within 1–21 days depending on
severity and aﬀected areas. A full blood count was normal
for all parameters 3 weeks after stopping the tablets.
4. Discussion
Inthisstudy,bothplaceboandEchinaceagroupsexperienced
respiratory illness during travel, which was indicated by
raised upper respiratory symptom scores and a higher
percentage of respiratory disease symptom-aﬀected partic-
ipants. This is an expected outcome as previous research
has reported increased medical issues including respiratory
symptoms associated with commercial ﬂights independent
of aircraft types [1]. Studies estimate the incidence of
respiratory problems between 11% as in ﬂight emergencies
based on respiratory problems [35] and 50% as health-
related problems with the 2nd most common cause being
respiratory problems [36]. Importantly, this study provides
some indication that, at return from travel, participants
using Echinacea displayed a lower respiratory symptom
score and the overall percentage of participants aﬀected by
respiratory disease symptoms was marginally lower in the
Echinacea group compared to placebo. This suggests that the
Echinacea treatment may had a protective eﬀect against the
development of respiratory symptoms during the period of
travel.
This study is the ﬁrst prevention trial for Echinacea use
that employs the recommended WURSS-44 as an outcome
measure for respiratory-illness-related QoL. In contrast to
a recent prevention trial [27] it describes a well-powered,
high-quality, placebo-controlled study. Moreover, it uses a
common scenario of travel as a risk factor of attracting
respiratory illness rather than artiﬁcial virus inoculation
[28].
The reported discrepancy in previous clinical trial results
for Echinacea is attributed to variations in applied out-
come measures, treatment protocols, and, most importantly,
varying Echinacea preparations [19, 20]. Speciﬁcally, the
evaluation of herbal study medications is essential for the
interpretation of clinical trial results [37], and the evidence
of eﬃcacy (and safety) for herbal medicines should be
considered to be extract speciﬁc [38]. This study utilised a
standardised Echinacea formulation for which a phytochem-
ical proﬁle and pharmacokinetic data exist [25] and whichEvidence-Based Complementary and Alternative Medicine 7
has been marketed for reducing the incidence and symptoms
of cold- and ﬂu-like symptoms in Australia, New Zealand,
the UK, the USA, Canada, and South Africa.
Similartothethreepreviouslymentionedpreventionand
inoculation trials where they used 7–14-day pre- and 5-day
postinoculation treatment [18, 28], participants in this study
were treated 14 days prior to travel, during travel, and 14
days after travel, thus using a similar pre-, but slightly longer
posttreatment. During travel (measured at return from
travel) the diﬀerences between the Echinacea and placebo
group were borderline signiﬁcant for symptom scores and
the number of participants who suﬀered from treatment
worthy respiratory disorder symptoms (scores of 17 and
above (RDS+)). This diﬀerence was further substantiated
during the 4 weeks after travel (measured at follow-up),
as a ∼50% relative reduction of illness in the Echinacea
treatedgroupcomparedtoplacebowasobserved.Ourresults
suggest that 1 in 2 patients who suﬀer RDS+ would have
beneﬁted from Echinacea supplementation during travel.
Of note, an inﬂuence of travel duration on the results is
excludedasnosigniﬁcantdiﬀerencewasfoundbetweenboth
treatment groups.
Preparations and dosing schedules used in previous
treatment and prevention trials vary widely [18, 19, 28]. Our
results indicate that the dosing chosen in this study will be
suﬃcient to have a beneﬁcial eﬀect on respiratory health
while travelling.
The WURSS-44 originally developed for the assessment
of patients aﬀected by cold and ﬂu [31]w a ss t r o n g l y
recommended for Echinacea trials [19] and was therefore
utilised in this study. Whether Echinacea will beneﬁt general
QoL is still debated [39], and whether it aﬀects headache,
sleep pattern, jet lag, and herpes simplex duration should
be investigated by future studies using appropriate outcome
measures.
NumeroushumantrialshavefoundthatEchinaceaiswell
tolerated with a slight risk of transient, reversible adverse
events involving mainly gastrointestinal upsets and rashes
[20, 40]. In rare cases, Echinacea can be associated with
allergic reactions that may be severe or exacerbate asthma
[40]. Hence, plant allergy and asthma became exclusion
criteriainthistrial.Asexpected,Echinaceawasgenerallywell
tolerated in this trial. We observed only two adverse events
which displayed a highly likely relationship to Echinacea as
they classiﬁed as allergic reactions and mimic description
of allergic reactions previously described for Echinacea [40].
Importantly, both participants recalled mild reactions to
some weeds in the past. Given these ﬁndings, it should be
considered to alert consumers and patients to the possibility
of allergic reactions to Echinacea if they are allergic to plants
in general. It is also important to note that one participant
hadtakenotherEchinaceaproductspreviouslywithoutexpe-
riencingadverseeﬀects.Thisagainhighlightstheimportance
of well-characterized and standardized herbal products to be
able to compare eﬃcacy and safety outcomes.
As with all RCTs, this study had several limitations.
Whilst diaries were used to document events during par-
ticipants’ travel and help with the recollection of dosing,
symptoms, and compliance, a certain amount of recall bias
hastobeexpectedwhenthesurveyswerecompletedatreturn
and followup. This study used travel including long-haul
intercontinental ﬂights, time zone, and climate change as a
model to see whether Echinacea is eﬀective in preventing
upper respiratory symptoms. Whether these ﬁndings can be
generalised for other populations is debatable. In addition,
the appropriateness of Echinacea use needs to be established
for each individual traveller, especially those suﬀering from
respiratory diseases (e.g., COPD, asthma, pneumonia) or
immune disorders as they belong to the group of people who
were excluded from this trial.
5. Conclusion
Although respiratory symptoms for both groups increased
signiﬁcantly during travel periods associated with long-haul
ﬂights, the increase of these symptoms for the Echinacea
group was signiﬁcantly lower than for the placebo group.
This highlights a beneﬁcial eﬀect from Echinacea supple-
mentation in adults if tablets contain 4.4mg alkylamides
from E. purpurea and E. angustifolia a n da r et a k e n1 4d a y s
before and during travel. The incidence of adverse eﬀects
was low and may be predicted by thoroughly assessing the
patient’s medical history for plant allergies and counselling
on the above-mentioned signs and symptoms of allergy thus
enabling consumers to stop Echinacea formulations at the
onset of an allergic response.
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